A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Launched by APELLIS PHARMACEUTICALS, INC. · Jun 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Pegcetacoplan to see if it can help adults who are at high risk of experiencing Delayed Graft Function (DGF) after receiving a kidney transplant from a deceased donor. DGF is a condition where the transplanted kidney does not work immediately and can lead to complications. The trial aims to determine if Pegcetacoplan can improve kidney function and safety during the recovery process.

To join this study, participants must be at least 18 years old and on dialysis for end-stage kidney disease while waiting for their first or second kidney transplant. They should have very low urine output and meet certain health requirements. Participants will receive the transplant and specific medications as part of the study. The trial is not yet recruiting, but those interested should discuss eligibility with their doctor. Overall, this study could provide valuable information on improving outcomes for kidney transplant patients at risk for DGF.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged at least 18 years
• • 2. Have end-stage kidney disease and be on the waiting list for a kidney transplant from a deceased donor.
• • 3. Be on dialysis at the time of your transplant and produce very little urine (less than 200 mL per day). You must have been on dialysis for at least 3 months.
• 4. Be receiving your first or second kidney transplant from a deceased donor. If this is your second transplant:
• • 1. It cannot be due to a serious infection or a serious blood clot in your previous transplant.
• • 2. Your calculated Panel Reactive Antibody (CPRA) level must be below 50%.
• • 5. Be getting a donor kidney that meets the study's specific requirements.
• 6. Be at low to medium risk of transplant rejection, and be scheduled to receive:
• • 1. A medication called ATG as part of your transplant procedure.
• • 2. Steroids (corticosteroids) as part of your treatment at the time of screening.
• • 3. A medication called tacrolimus (or a similar drug) after your transplant, according to usual medical practice.
• 7. Have received certain vaccines before starting the study treatment, specifically:
• • 1. Pneumococcal (S. pneumoniae)
• • 2. Meningococcal (N. meningitidis types A, C, W, Y, and B)
• • 3. Haemophilus influenzae type B
• • If you haven't had these vaccines, you may still qualify if you're medically shown not to respond to them and your doctor has a plan to give you preventive antibiotics, with the sponsor's approval.
• Exclusion Criteria:
• • 1. Have taken part in another medical research study or used an experimental drug, treatment, or device in the past 30 days (or longer, depending on the drug).
• • 2. Have recently used certain medications that affect the immune system, such as rituximab, belimumab, or other approved complement-blocking drugs.
• • 3. Weigh less than 20kg or more than 120kg at screening.
• 4. Have or had recently had any of the following infections:
• • 1. Hepatitis B or Hepatitis C (unless treated and no longer active).
• • 2. HIV (human immunodeficiency virus) at any time.
• 5. Have had cancer in the past 5 years, unless it was:
• • 1. A small, treated skin cancer (like basal or squamous cell), or
• • 2. A very small kidney cancer that was found early and treated.
• • 6. Have received any other organ transplant (except for one previous kidney transplant), or are scheduled for a transplant involving more than one organ.